ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Direct Acting Antivirals Market Research Report 2024
Published Date: September 2024
|
Report Code: QYRE-Auto-13H18356
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Direct Acting Antivirals Market Research Report 2024
BUY CHAPTERS

Global Direct Acting Antivirals Market Research Report 2024

Code: QYRE-Auto-13H18356
Report
September 2024
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Gilead Sciences
Merck
AbbVie
Bristol–Myers Squibb
Ascletis Pharma
Kawin Technology
Yichang Hec Changjiang Pharmaceutical
Sanhome Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Cosunter Pharmaceutical
Beijing Sihuan Pharmaceutical
Asegua Therapeutics

Direct Acting Antivirals Market

Direct-Acting Antivirals (DAAs) are a class of medications designed to treat chronic hepatitis C by targeting specific stages of the hepatitis C virus's life cycle. Unlike older treatments, which involved interferon and were often less effective and had more side effects, DAAs directly inhibit key viral enzymes and proteins essential for the virus's replication and assembly. By blocking these targets, DAAs effectively suppress the virus with high cure rates and fewer side effects.
The global Direct Acting Antivirals market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
The development of Direct-Acting Antivirals (DAAs) represents a significant leap in the treatment of chronic hepatitis C, transforming it from a condition often associated with prolonged and challenging therapy to one that can be cured with relative ease. Early DAAs, such as protease inhibitors, were pivotal in shifting the paradigm from interferon-based therapies, which had substantial side effects and variable efficacy. The introduction of these initial DAAs marked the beginning of a new era, offering patients more effective and tolerable treatment options.
As research advanced, the focus shifted to developing more refined and potent DAAs with improved safety profiles and higher cure rates. The incorporation of multiple classes of DAAs—such as NS5A inhibitors and NS5B polymerase inhibitors—into combination therapies led to significant breakthroughs. These combination regimens, often administered as fixed-dose pills, allowed for shorter treatment durations and better outcomes, further reducing the incidence of treatment-related complications and improving patient adherence.
Looking ahead, the trend in DAAs development is likely to continue towards optimizing treatment regimens and expanding their application. This includes exploring new combinations to address different genotypes and resistant strains of hepatitis C, as well as investigating the potential use of DAAs in treating other viral infections. Innovations in drug delivery systems and personalized medicine are expected to further enhance the effectiveness and accessibility of DAAs, continuing to advance the field of antiviral therapy and improve patient outcomes globally.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Direct Acting Antivirals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct Acting Antivirals.
The Direct Acting Antivirals market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Direct Acting Antivirals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Direct Acting Antivirals manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Direct Acting Antivirals Market Report

Report Metric Details
Report Name Direct Acting Antivirals Market
Segment by Type
  • Pangenotypic
  • Genotype-Specific
Segment by Application
  • Hospital and Clinic
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Gilead Sciences, Asegua Therapeutics, Merck, AbbVie, Bristol Myers Squibb, Ascletis Pharma, Kawin Technology, YiChang HEC ChangJiang Pharmaceutical, Sanhome Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Cosunter pharmaceutical, Beijing Sihuan Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Direct Acting Antivirals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Direct Acting Antivirals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Direct Acting Antivirals Market report?

Ans: The main players in the Direct Acting Antivirals Market are Gilead Sciences, Asegua Therapeutics, Merck, AbbVie, Bristol Myers Squibb, Ascletis Pharma, Kawin Technology, YiChang HEC ChangJiang Pharmaceutical, Sanhome Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Cosunter pharmaceutical, Beijing Sihuan Pharmaceutical

What are the Application segmentation covered in the Direct Acting Antivirals Market report?

Ans: The Applications covered in the Direct Acting Antivirals Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the Direct Acting Antivirals Market report?

Ans: The Types covered in the Direct Acting Antivirals Market report are Pangenotypic, Genotype-Specific

Recommended Reports

Hepatitis & Liver Therapies

Hepatitis C Market

Antivirals & RNA Drugs

1 Direct Acting Antivirals Market Overview
1.1 Product Definition
1.2 Direct Acting Antivirals by Type
1.2.1 Global Direct Acting Antivirals Market Value Comparison by Type (2024-2030)
1.2.2 Pangenotypic
1.2.3 Genotype-Specific
1.3 Direct Acting Antivirals by Application
1.3.1 Global Direct Acting Antivirals Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Direct Acting Antivirals Market Size Estimates and Forecasts
1.4.1 Global Direct Acting Antivirals Revenue 2019-2030
1.4.2 Global Direct Acting Antivirals Sales 2019-2030
1.4.3 Global Direct Acting Antivirals Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Direct Acting Antivirals Market Competition by Manufacturers
2.1 Global Direct Acting Antivirals Sales Market Share by Manufacturers (2019-2024)
2.2 Global Direct Acting Antivirals Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Direct Acting Antivirals Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Direct Acting Antivirals, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Direct Acting Antivirals, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Direct Acting Antivirals, Product Type & Application
2.7 Global Key Manufacturers of Direct Acting Antivirals, Date of Enter into This Industry
2.8 Global Direct Acting Antivirals Market Competitive Situation and Trends
2.8.1 Global Direct Acting Antivirals Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Direct Acting Antivirals Players Market Share by Revenue
2.8.3 Global Direct Acting Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Direct Acting Antivirals Market Scenario by Region
3.1 Global Direct Acting Antivirals Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Direct Acting Antivirals Sales by Region: 2019-2030
3.2.1 Global Direct Acting Antivirals Sales by Region: 2019-2024
3.2.2 Global Direct Acting Antivirals Sales by Region: 2025-2030
3.3 Global Direct Acting Antivirals Revenue by Region: 2019-2030
3.3.1 Global Direct Acting Antivirals Revenue by Region: 2019-2024
3.3.2 Global Direct Acting Antivirals Revenue by Region: 2025-2030
3.4 North America Direct Acting Antivirals Market Facts & Figures by Country
3.4.1 North America Direct Acting Antivirals Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Direct Acting Antivirals Sales by Country (2019-2030)
3.4.3 North America Direct Acting Antivirals Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Direct Acting Antivirals Market Facts & Figures by Country
3.5.1 Europe Direct Acting Antivirals Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Direct Acting Antivirals Sales by Country (2019-2030)
3.5.3 Europe Direct Acting Antivirals Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Direct Acting Antivirals Market Facts & Figures by Region
3.6.1 Asia Pacific Direct Acting Antivirals Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Direct Acting Antivirals Sales by Region (2019-2030)
3.6.3 Asia Pacific Direct Acting Antivirals Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Direct Acting Antivirals Market Facts & Figures by Country
3.7.1 Latin America Direct Acting Antivirals Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Direct Acting Antivirals Sales by Country (2019-2030)
3.7.3 Latin America Direct Acting Antivirals Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Direct Acting Antivirals Market Facts & Figures by Country
3.8.1 Middle East and Africa Direct Acting Antivirals Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Direct Acting Antivirals Sales by Country (2019-2030)
3.8.3 Middle East and Africa Direct Acting Antivirals Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Direct Acting Antivirals Sales by Type (2019-2030)
4.1.1 Global Direct Acting Antivirals Sales by Type (2019-2024)
4.1.2 Global Direct Acting Antivirals Sales by Type (2025-2030)
4.1.3 Global Direct Acting Antivirals Sales Market Share by Type (2019-2030)
4.2 Global Direct Acting Antivirals Revenue by Type (2019-2030)
4.2.1 Global Direct Acting Antivirals Revenue by Type (2019-2024)
4.2.2 Global Direct Acting Antivirals Revenue by Type (2025-2030)
4.2.3 Global Direct Acting Antivirals Revenue Market Share by Type (2019-2030)
4.3 Global Direct Acting Antivirals Price by Type (2019-2030)
5 Segment by Application
5.1 Global Direct Acting Antivirals Sales by Application (2019-2030)
5.1.1 Global Direct Acting Antivirals Sales by Application (2019-2024)
5.1.2 Global Direct Acting Antivirals Sales by Application (2025-2030)
5.1.3 Global Direct Acting Antivirals Sales Market Share by Application (2019-2030)
5.2 Global Direct Acting Antivirals Revenue by Application (2019-2030)
5.2.1 Global Direct Acting Antivirals Revenue by Application (2019-2024)
5.2.2 Global Direct Acting Antivirals Revenue by Application (2025-2030)
5.2.3 Global Direct Acting Antivirals Revenue Market Share by Application (2019-2030)
5.3 Global Direct Acting Antivirals Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Sciences Direct Acting Antivirals Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 Asegua Therapeutics
6.2.1 Asegua Therapeutics Company Information
6.2.2 Asegua Therapeutics Description and Business Overview
6.2.3 Asegua Therapeutics Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Asegua Therapeutics Direct Acting Antivirals Product Portfolio
6.2.5 Asegua Therapeutics Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Direct Acting Antivirals Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Company Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AbbVie Direct Acting Antivirals Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 Bristol Myers Squibb
6.5.1 Bristol Myers Squibb Company Information
6.5.2 Bristol Myers Squibb Description and Business Overview
6.5.3 Bristol Myers Squibb Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bristol Myers Squibb Direct Acting Antivirals Product Portfolio
6.5.5 Bristol Myers Squibb Recent Developments/Updates
6.6 Ascletis Pharma
6.6.1 Ascletis Pharma Company Information
6.6.2 Ascletis Pharma Description and Business Overview
6.6.3 Ascletis Pharma Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Ascletis Pharma Direct Acting Antivirals Product Portfolio
6.6.5 Ascletis Pharma Recent Developments/Updates
6.7 Kawin Technology
6.7.1 Kawin Technology Company Information
6.7.2 Kawin Technology Description and Business Overview
6.7.3 Kawin Technology Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Kawin Technology Direct Acting Antivirals Product Portfolio
6.7.5 Kawin Technology Recent Developments/Updates
6.8 YiChang HEC ChangJiang Pharmaceutical
6.8.1 YiChang HEC ChangJiang Pharmaceutical Company Information
6.8.2 YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
6.8.3 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.8.4 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio
6.8.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
6.9 Sanhome Pharmaceutical
6.9.1 Sanhome Pharmaceutical Company Information
6.9.2 Sanhome Pharmaceutical Description and Business Overview
6.9.3 Sanhome Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio
6.9.5 Sanhome Pharmaceutical Recent Developments/Updates
6.10 Chia Tai Tianqing Pharmaceutical
6.10.1 Chia Tai Tianqing Pharmaceutical Company Information
6.10.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.10.3 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio
6.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.11 Cosunter pharmaceutical
6.11.1 Cosunter pharmaceutical Company Information
6.11.2 Cosunter pharmaceutical Description and Business Overview
6.11.3 Cosunter pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio
6.11.5 Cosunter pharmaceutical Recent Developments/Updates
6.12 Beijing Sihuan Pharmaceutical
6.12.1 Beijing Sihuan Pharmaceutical Company Information
6.12.2 Beijing Sihuan Pharmaceutical Description and Business Overview
6.12.3 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio
6.12.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Direct Acting Antivirals Industry Chain Analysis
7.2 Direct Acting Antivirals Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Direct Acting Antivirals Production Mode & Process
7.4 Direct Acting Antivirals Sales and Marketing
7.4.1 Direct Acting Antivirals Sales Channels
7.4.2 Direct Acting Antivirals Distributors
7.5 Direct Acting Antivirals Customers
8 Direct Acting Antivirals Market Dynamics
8.1 Direct Acting Antivirals Industry Trends
8.2 Direct Acting Antivirals Market Drivers
8.3 Direct Acting Antivirals Market Challenges
8.4 Direct Acting Antivirals Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Gilead Sciences
Merck
AbbVie
Bristol–Myers Squibb
Ascletis Pharma
Kawin Technology
Yichang Hec Changjiang Pharmaceutical
Sanhome Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Cosunter Pharmaceutical
Beijing Sihuan Pharmaceutical
Asegua Therapeutics
List of Tables
 Table 1. Global Direct Acting Antivirals Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Direct Acting Antivirals Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Direct Acting Antivirals Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Direct Acting Antivirals Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Direct Acting Antivirals Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Direct Acting Antivirals Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Direct Acting Antivirals Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Direct Acting Antivirals Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Direct Acting Antivirals, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Direct Acting Antivirals, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Direct Acting Antivirals, Product Type & Application
 Table 12. Global Key Manufacturers of Direct Acting Antivirals, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Direct Acting Antivirals by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct Acting Antivirals as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Direct Acting Antivirals Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Direct Acting Antivirals Sales by Region (2019-2024) & (K Units)
 Table 18. Global Direct Acting Antivirals Sales Market Share by Region (2019-2024)
 Table 19. Global Direct Acting Antivirals Sales by Region (2025-2030) & (K Units)
 Table 20. Global Direct Acting Antivirals Sales Market Share by Region (2025-2030)
 Table 21. Global Direct Acting Antivirals Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Direct Acting Antivirals Revenue Market Share by Region (2019-2024)
 Table 23. Global Direct Acting Antivirals Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Direct Acting Antivirals Revenue Market Share by Region (2025-2030)
 Table 25. North America Direct Acting Antivirals Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Direct Acting Antivirals Sales by Country (2019-2024) & (K Units)
 Table 27. North America Direct Acting Antivirals Sales by Country (2025-2030) & (K Units)
 Table 28. North America Direct Acting Antivirals Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Direct Acting Antivirals Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Direct Acting Antivirals Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Direct Acting Antivirals Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Direct Acting Antivirals Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Direct Acting Antivirals Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Direct Acting Antivirals Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Direct Acting Antivirals Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Direct Acting Antivirals Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Direct Acting Antivirals Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Direct Acting Antivirals Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Direct Acting Antivirals Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Direct Acting Antivirals Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Direct Acting Antivirals Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Direct Acting Antivirals Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Direct Acting Antivirals Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Direct Acting Antivirals Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Direct Acting Antivirals Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Direct Acting Antivirals Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Direct Acting Antivirals Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Direct Acting Antivirals Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Direct Acting Antivirals Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Direct Acting Antivirals Sales (K Units) by Type (2019-2024)
 Table 51. Global Direct Acting Antivirals Sales (K Units) by Type (2025-2030)
 Table 52. Global Direct Acting Antivirals Sales Market Share by Type (2019-2024)
 Table 53. Global Direct Acting Antivirals Sales Market Share by Type (2025-2030)
 Table 54. Global Direct Acting Antivirals Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Direct Acting Antivirals Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Direct Acting Antivirals Revenue Market Share by Type (2019-2024)
 Table 57. Global Direct Acting Antivirals Revenue Market Share by Type (2025-2030)
 Table 58. Global Direct Acting Antivirals Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Direct Acting Antivirals Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Direct Acting Antivirals Sales (K Units) by Application (2019-2024)
 Table 61. Global Direct Acting Antivirals Sales (K Units) by Application (2025-2030)
 Table 62. Global Direct Acting Antivirals Sales Market Share by Application (2019-2024)
 Table 63. Global Direct Acting Antivirals Sales Market Share by Application (2025-2030)
 Table 64. Global Direct Acting Antivirals Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Direct Acting Antivirals Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Direct Acting Antivirals Revenue Market Share by Application (2019-2024)
 Table 67. Global Direct Acting Antivirals Revenue Market Share by Application (2025-2030)
 Table 68. Global Direct Acting Antivirals Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Direct Acting Antivirals Price (US$/Unit) by Application (2025-2030)
 Table 70. Gilead Sciences Company Information
 Table 71. Gilead Sciences Description and Business Overview
 Table 72. Gilead Sciences Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Gilead Sciences Direct Acting Antivirals Product
 Table 74. Gilead Sciences Recent Developments/Updates
 Table 75. Asegua Therapeutics Company Information
 Table 76. Asegua Therapeutics Description and Business Overview
 Table 77. Asegua Therapeutics Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Asegua Therapeutics Direct Acting Antivirals Product
 Table 79. Asegua Therapeutics Recent Developments/Updates
 Table 80. Merck Company Information
 Table 81. Merck Description and Business Overview
 Table 82. Merck Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Merck Direct Acting Antivirals Product
 Table 84. Merck Recent Developments/Updates
 Table 85. AbbVie Company Information
 Table 86. AbbVie Description and Business Overview
 Table 87. AbbVie Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. AbbVie Direct Acting Antivirals Product
 Table 89. AbbVie Recent Developments/Updates
 Table 90. Bristol Myers Squibb Company Information
 Table 91. Bristol Myers Squibb Description and Business Overview
 Table 92. Bristol Myers Squibb Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Bristol Myers Squibb Direct Acting Antivirals Product
 Table 94. Bristol Myers Squibb Recent Developments/Updates
 Table 95. Ascletis Pharma Company Information
 Table 96. Ascletis Pharma Description and Business Overview
 Table 97. Ascletis Pharma Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Ascletis Pharma Direct Acting Antivirals Product
 Table 99. Ascletis Pharma Recent Developments/Updates
 Table 100. Kawin Technology Company Information
 Table 101. Kawin Technology Description and Business Overview
 Table 102. Kawin Technology Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Kawin Technology Direct Acting Antivirals Product
 Table 104. Kawin Technology Recent Developments/Updates
 Table 105. YiChang HEC ChangJiang Pharmaceutical Company Information
 Table 106. YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
 Table 107. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product
 Table 109. YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
 Table 110. Sanhome Pharmaceutical Company Information
 Table 111. Sanhome Pharmaceutical Description and Business Overview
 Table 112. Sanhome Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Sanhome Pharmaceutical Direct Acting Antivirals Product
 Table 114. Sanhome Pharmaceutical Recent Developments/Updates
 Table 115. Chia Tai Tianqing Pharmaceutical Company Information
 Table 116. Chia Tai Tianqing Pharmaceutical Description and Business Overview
 Table 117. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product
 Table 119. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
 Table 120. Cosunter pharmaceutical Company Information
 Table 121. Cosunter pharmaceutical Description and Business Overview
 Table 122. Cosunter pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Cosunter pharmaceutical Direct Acting Antivirals Product
 Table 124. Cosunter pharmaceutical Recent Developments/Updates
 Table 125. Beijing Sihuan Pharmaceutical Company Information
 Table 126. Beijing Sihuan Pharmaceutical Description and Business Overview
 Table 127. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product
 Table 129. Beijing Sihuan Pharmaceutical Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Direct Acting Antivirals Distributors List
 Table 133. Direct Acting Antivirals Customers List
 Table 134. Direct Acting Antivirals Market Trends
 Table 135. Direct Acting Antivirals Market Drivers
 Table 136. Direct Acting Antivirals Market Challenges
 Table 137. Direct Acting Antivirals Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Direct Acting Antivirals
 Figure 2. Global Direct Acting Antivirals Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Direct Acting Antivirals Market Share by Type: 2023 & 2030
 Figure 4. Pangenotypic Product Picture
 Figure 5. Genotype-Specific Product Picture
 Figure 6. Global Direct Acting Antivirals Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global Direct Acting Antivirals Market Share by Application: 2023 & 2030
 Figure 8. Hospital and Clinic
 Figure 9. Pharmacy
 Figure 10. Other
 Figure 11. Global Direct Acting Antivirals Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Direct Acting Antivirals Market Size (2019-2030) & (US$ Million)
 Figure 13. Global Direct Acting Antivirals Sales (2019-2030) & (K Units)
 Figure 14. Global Direct Acting Antivirals Average Price (US$/Unit) & (2019-2030)
 Figure 15. Direct Acting Antivirals Report Years Considered
 Figure 16. Direct Acting Antivirals Sales Share by Manufacturers in 2023
 Figure 17. Global Direct Acting Antivirals Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest Direct Acting Antivirals Players: Market Share by Revenue in Direct Acting Antivirals in 2023
 Figure 19. Direct Acting Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global Direct Acting Antivirals Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America Direct Acting Antivirals Sales Market Share by Country (2019-2030)
 Figure 22. North America Direct Acting Antivirals Revenue Market Share by Country (2019-2030)
 Figure 23. United States Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe Direct Acting Antivirals Sales Market Share by Country (2019-2030)
 Figure 26. Europe Direct Acting Antivirals Revenue Market Share by Country (2019-2030)
 Figure 27. Germany Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific Direct Acting Antivirals Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific Direct Acting Antivirals Revenue Market Share by Region (2019-2030)
 Figure 34. China Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America Direct Acting Antivirals Sales Market Share by Country (2019-2030)
 Figure 42. Mexico Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa Direct Acting Antivirals Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa Direct Acting Antivirals Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE Direct Acting Antivirals Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of Direct Acting Antivirals by Type (2019-2030)
 Figure 52. Global Revenue Market Share of Direct Acting Antivirals by Type (2019-2030)
 Figure 53. Global Direct Acting Antivirals Price (US$/Unit) by Type (2019-2030)
 Figure 54. Global Sales Market Share of Direct Acting Antivirals by Application (2019-2030)
 Figure 55. Global Revenue Market Share of Direct Acting Antivirals by Application (2019-2030)
 Figure 56. Global Direct Acting Antivirals Price (US$/Unit) by Application (2019-2030)
 Figure 57. Direct Acting Antivirals Value Chain
 Figure 58. Direct Acting Antivirals Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Global Antiviral Drugs for the Treatment of Hepatitis C HCV Market Research Report 2024
Hepatitis C Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hepatitis C Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ledipasvir Market Insights Forecast to 2030
Global Direct Oral Anticoagulants DOACs Market Research Report 2024
Global Hepatitis C Interferon Market Research Report 2024
Global Anti Hepatitis C Drugs Market Research Report 2024
Global Nucleic Acid Drugs Market Research Report 2025
Global Influenza Flu Antiviral Drugs Market Insights Forecast to 2030
Direct acting Antiviral Drugs Market
Global Hepatitis C Treatment Drug Market Research Report 2024
Protease Inhibitors Market
Antivirals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global RNA based Therapeutics Drug Market Research Report 2024
Global Nucleic acid based Therapeutics Drug Market Research Report 2024
Global Nucleic Acid Therapeutic Market Research Report 2024
Global Nucleic Acid based Therapy Market Research Report 2024
Neuraminidase Inhibitors Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Long acting Interferon Injection Market Research Report 2024
Global Ophthalmic Antivirals Market Research Report 2025

RELATED REPORTS

Global Hepatitis B Virus Core Antibody Diagnostic Kits Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21N6899
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Pediatric Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13M6952
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Poliomyelitis Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29X7355
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Varicella Virus (Chickenpox) Vaccine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28B293
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions